P3 Health Partners Inc. Liquidation Value

PIII Healthcare Services

Cash & Equivalents

$25.50M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $25.50M
Total Obligations: -$806.71M
$-781.22M
Per share: $-237.60
Period: 2026-03-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $25.50M
AR: N/A
Total Obligations: -$806.71M
$-781.22M
Per share: $-237.60
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Accounts Receivable: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $25.50M
AR: N/A
Inventory: N/A
Total Obligations: -$806.71M
$-781.22M
Per share: $-237.60
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Accounts Receivable: not reported in this period (annual-only)
  • Inventory: not reported

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-781.22M$-237.60
Liquid Liquidation Value$-781.22M$-237.60
Operating Liquidation Value$-781.22M$-237.60

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-14. View on SEC EDGAR →

Cash & Equivalents$25.50M
Accounts ReceivableN/A
InventoryN/A
Current Liabilities$525.49M
Long-term Debt (?)$259.57M
Op. Lease Liability (?)$10.83M
Finance Lease (?)N/A
Shares Outstanding3.3M

Explore all 79 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$25.50MN/AN/A$11.67M$525.49M$259.57M$10.83MN/A
2025-12-31$25.01MN/AN/A$11.71M$545.26M$228.37M$11.47MN/A
2025-09-30$37.71MN/AN/A$9.93M$423.95M$214.18M$12.05MN/A
2025-06-30$38.58MN/AN/A$14.39M$505.00M$101.96M$10.31MN/A
2025-03-31$40.08MN/AN/A$11.50M$507.03M$106.12M$10.98MN/A
2024-12-31$38.82MN/AN/A$8.44M$496.42M$108.91M$11.34MN/A
2024-09-30$62.96MN/AN/A$13.47M$405.32M$133.23M$11.16MN/A
2024-06-30$73.09MN/AN/A$7.99M$352.25M$133.12M$12.19MN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-14 View
2025-12-31 10-K 2026-03-26 View
2025-09-30 10-Q 2025-11-14 View
2025-06-30 10-Q 2025-08-14 View
2025-03-31 10-Q 2025-05-15 View
2024-12-31 10-K 2025-03-28 View
2024-09-30 10-Q 2024-11-12 View
2024-06-30 10-Q 2024-08-07 View

AI Insights

AI Insight·Generated 2026-05-15

P3 Health Partners Inc. (PIII) carries a deeply negative liquidation posture as of March 31, 2026. MFFAIS-computed liquidation values (CLV/LLV/OLV) are all negative $774 million, consistent with the balance-sheet structure visible in the filing. The asset base is dominated by goodwill and intangibles (both zeroed under liquidation haircuts), health plan receivables (recoverable at 90-95% but subject to counterparty risk given related-party concentration with Atrio), and $25.5 million of unrestricted cash. Against these assets, the liability stack includes: (1) a CRG Term Loan Facility (secured, senior), (2) five tranches of CPF-affiliated unsecured promissory notes (VGS 1-5) with an aggregate face value of approximately $252.5 million as of the balance sheet date, accruing at rates up to 19.5% per annum with PIK elections, plus back-end fees and warrants, (3) claims payable of approximately $176.5 million owed to related-party Atrio Health Plans, and (4) a premium deficiency reserve liability. Total long-term debt attributable to the VGS notes was tagged at $192.8 million (net of OID/issuance costs), up from $156.7 million at December 31, 2025, reflecting continued PIK accretion and draw activity under VGS 5. The filing contains an explicit going-concern qualification: management concluded that existing cash resources are insufficient to fund operations for at least one year from the filing date. Post-balance-sheet (April 27, 2026), the company executed a Debt Exchange Agreement converting the full $252.5 million VGS 1-5 balance into non-convertible, non-voting cumulative preferred stock (Series A at 13.5%, Series B at 17.5%, Series C at 19.5%) plus a Securities Purchase Agreement for up to $70 million of new Series D 19.5% cumulative preferred stock. This exchange removes funded debt from the balance sheet prospectively but inserts a senior preferred equity stack with high cumulative dividend rates and liquidation priority over common equity, leaving the common equity recovery position unchanged as effectively zero. The Term Loan Facility (CRG) remains outstanding and senior secured. Intangibles and goodwill on the consolidated balance sheet (carrying approximately $21 million quarterly D&A and substantial book value) contribute zero to liquidation recovery. The VIE structure (P3 LLC, MSO, CPC ACO) adds consolidation complexity but does not improve recovery: the MSO/CPC ACO VIE shows $17.5 million in assets against $14.7 million in liabilities as of March 31, 2026. The filing discusses the TRA liability (estimated $12.4 million unrecorded), DOJ civil investigative demand, and $9.8 million accrued liability to related-party Allymar, none of which are separately XBRL-tagged in the TAG_CONTEXT provided. TAG_CONTEXT is empty, so no tag_insights are reported.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...